Literature DB >> 17574121

Regulation of angiogenesis by Eph-ephrin interactions.

Sanne Kuijper1, Christopher J Turner, Ralf H Adams.   

Abstract

The large families of Eph receptor tyrosine kinases and their ephrin ligands transduce signals in a cell-cell contact-dependent fashion and thereby coordinate the growth, differentiation, and patterning of almost every organ and tissue. Eph-ephrin interactions can trigger a wide array of cellular responses, including cell adhesion, boundary formation, and repulsion. The exact mechanisms leading to this diversity of responses are unclear but appear to involve differential signaling, proteolytic cleavage of ephrins, and endocytosis of the ligand-receptor complex. In the developing cardiovascular system, Eph and ephrin molecules control the angiogenic remodeling of blood vessels and lymphatic vessels and play essential roles in endothelial cells as well as in supporting pericytes and vascular smooth muscle cells. Recent evidence suggests that Ephs and ephrins may also be involved in pathological angiogenesis, in particular, the neovascularization of tumors. Consequently, the expression, interactions, or signaling of Eph-ephrin molecules might be targets for future therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17574121     DOI: 10.1016/j.tcm.2007.03.003

Source DB:  PubMed          Journal:  Trends Cardiovasc Med        ISSN: 1050-1738            Impact factor:   6.677


  105 in total

1.  Eph/ephrin interactions modulate muscle satellite cell motility and patterning.

Authors:  Danny A Stark; Rowan M Karvas; Ashley L Siegel; D D W Cornelison
Journal:  Development       Date:  2011-11-09       Impact factor: 6.868

Review 2.  Targeting Eph receptors with peptides and small molecules: progress and challenges.

Authors:  Roberta Noberini; Ilaria Lamberto; Elena B Pasquale
Journal:  Semin Cell Dev Biol       Date:  2011-10-25       Impact factor: 7.727

3.  Preeclampsia up-regulates angiogenesis-associated microRNA (i.e., miR-17, -20a, and -20b) that target ephrin-B2 and EPHB4 in human placenta.

Authors:  Wen Wang; Lin Feng; Honghai Zhang; Stephanie Hachy; Seiro Satohisa; Louise C Laurent; Mana Parast; Jing Zheng; Dong-bao Chen
Journal:  J Clin Endocrinol Metab       Date:  2012-03-21       Impact factor: 5.958

4.  Crystallization and preliminary X-ray diffraction analysis of the complex of a human anti-ephrin type-A receptor 2 antibody fragment and its cognate antigen.

Authors:  Vaheh Oganesyan; Melissa M Damschroder; Sandrina Phipps; Susan D Wilson; Kimberly E Cook; Herren Wu; William F Dall'Acqua
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2010-05-29

5.  Brain pericytes: emerging concepts and functional roles in brain homeostasis.

Authors:  Masahiro Kamouchi; Tetsuro Ago; Takanari Kitazono
Journal:  Cell Mol Neurobiol       Date:  2011-03       Impact factor: 5.046

Review 6.  miRNAs as therapeutic targets in ischemic heart disease.

Authors:  Robert J A Frost; Eva van Rooij
Journal:  J Cardiovasc Transl Res       Date:  2010-03-30       Impact factor: 4.132

7.  Altered vascular expression of EphrinB2 and EphB4 in a model of oxygen-induced retinopathy.

Authors:  Michael H Davies; Andrew J Stempel; Kristin E Hubert; Michael R Powers
Journal:  Dev Dyn       Date:  2010-06       Impact factor: 3.780

8.  Endothelial cells regulate cardiomyocyte development from embryonic stem cells.

Authors:  Kang Chen; Hao Bai; Melanie Arzigian; Yong-Xing Gao; Jing Bao; Wen-Shu Wu; Wei-Feng Shen; Liqun Wu; Zack Z Wang
Journal:  J Cell Biochem       Date:  2010-09-01       Impact factor: 4.429

9.  Soluble ephrin-B2 mediates apoptosis in retinal neovascularization and in endothelial cells.

Authors:  Michael H Davies; David O Zamora; Justine R Smith; Michael R Powers
Journal:  Microvasc Res       Date:  2009-02-13       Impact factor: 3.514

10.  Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis.

Authors:  Yung Hae Kim; Huiqing Hu; Salvador Guevara-Gallardo; Michael T Y Lam; Shun-Yin Fong; Rong A Wang
Journal:  Development       Date:  2008-11       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.